Form 4: Vaxcyte CFO Reports Routine Stock Transactions for Tax

Vaxcyte's President and CFO, Andrew Guggenhime, reported the surrender of shares to cover tax withholding obligations related to RSU vesting.

Summary

• Andrew Guggenhime, President and CFO of Vaxcyte, Inc. (PCVX), reported transactions involving common stock.
• On September 2, 2025, a total of 5,080 shares of common stock were surrendered to the Issuer.
• These shares were surrendered to cover applicable tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The shares were valued at a price of $31.56 per share for the purpose of these transactions.
• Following these reported transactions, Andrew Guggenhime beneficially owns 127,199 shares of Vaxcyte common stock directly.
• The reported beneficial ownership includes 329 shares acquired under Vaxcyte's Employee Stock Purchase Plan on May 16, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which does not reflect a discretionary sale or purchase by the insider.

Positives

• The underlying event, the vesting of Restricted Stock Units (RSUs), represents a positive compensation event for the executive.

Negatives

• A reduction in direct beneficial ownership of 5,080 shares occurred due to tax withholding, which is a non-discretionary disposition.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains solely to past insider transactions.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries when executives' Restricted Stock Units (RSUs) vest and shares are withheld to cover tax liabilities. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The transaction type (F code for tax withholding) is a standard practice for executives receiving equity compensation across publicly traded companies, aligning with typical corporate governance and compensation structures.

Stakeholder Impact

• Shareholders: The transaction is a routine administrative event and is unlikely to have a significant direct impact on the company's stock price or long-term value.
• Employees: The RSU vesting and subsequent tax withholding are standard components of executive compensation, reflecting the company's equity incentive programs.

Key Dates

Recommendation

The filing details a routine, non-discretionary transaction by an insider to cover tax obligations upon RSU vesting. This type of transaction does not indicate a change in the insider's view of the company's fundamentals or future prospects, nor does it suggest any new material information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the investment thesis.

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, RSU Vesting, Tax Withholding, Andrew Guggenhime, Common Stock